Intravascular Ultrasound Tissue Ablation for Restenosis
Official title: Intravascular Ultrasonic Tissue Ablation (IVUS-TA) for Treatment of In-stent Restenosis
Funded at North Carolina State University Raleigh · NIH-11441910 · Data updated 2026-11-12
A new catheter-based ultrasound approach aims to safely remove excess tissue inside stents to prevent repeat vessel narrowing after a stent procedure.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | North Carolina State University Raleigh NIH-funded |
| Lab location | 1 site (Raleigh, United States) |
| Project start | September 2, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $73,776 |
| NIH project number | 1R03EB040286-01 |
| Project ID | NIH-11441910 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with in-stent restenosis who are candidates for catheter-based therapy and have suitable vascular anatomy for ultrasound-based treatment.
✕Less likely to help
Patients without restenosis or with anatomy unsuitable for intravascular ultrasound energy delivery may not benefit.
What this research studies
This project develops a tiny high-frequency ultrasound device that can be threaded through a catheter to deliver targeted energy inside a narrowed artery. Researchers will test how well the system ablates tissue and how safely it heats surrounding areas using lab models and realistic artery phantoms. The goal is to create a minimally invasive option for treating restenosis that could reduce the need for repeat procedures. Results from ex-vivo tests will lay the groundwork for future animal and clinical studies.
Why it matters
Potential benefit: If successful, IVUS-TA could offer a safer, more effective way to treat in-stent restenosis with fewer complications and less vessel injury.
How similar studies have gone: Previous approaches to treat restenosis have limited success; this represents a novel, early-stage technology with potential for meaningful impact if proven safe and effective.
Where this research is happening
-
North Carolina State University Raleigh
Raleigh, United States Active
Researchers
- Principal investigator: Wu, Huaiyu — North Carolina State University Raleigh
- Study coordinator: Wu, Huaiyu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.